5-(3-fluoro-5-(4-morpholino)benzamido)indole | 616243-06-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 5-(3-fluoro-5-(4-morpholino)benzamido)indole
• 英文别名: 3-Fluoro-N-1H-indol-5-YL-5-morpholin-4-ylbenzamide；3-fluoro-N-(1H-indol-5-yl)-5-morpholin-4-ylbenzamide
• CAS: 616243-06-2
• 化学式: C₁₉H₁₈FN₃O₂
• 分子量: 339.369
• InChiKey: VMLSXFMXUNVCSK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  25
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  57.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• Pharmaceutical compounds
  申请人：Frederickson Martyn

  公开号：US20050124620A1

  公开（公告）日：2005-06-09

  Compounds are disclosed of the formula (I): in which U, T, V and W are each a nitrogen atom or carbon atom. When U, T, V or W is a carbon atom, it may be substituted. The compounds are inhibitors of p38 MAP kinase and are useful for treating inflammatory diseases such as arthritis. An example of such a compound is:

  公式（I）的化合物被披露，其中U、T、V和W分别是氮原子或碳原子。当U、T、V或W是碳原子时，它可以被取代。这些化合物是p38 MAP激酶的抑制剂，可用于治疗炎症性疾病，如关节炎。这样的化合物的一个例子是：
• HETEROCYCLIC COMPOUNDS AND THEIR USE AS MODULATORS OF P38 MAP KINASE
  申请人：Astex Technology Limited

  公开号：EP1495016A2

  公开（公告）日：2005-01-12
• REGULATED BIOCIRCUIT SYSTEMS
  申请人：Obsidian Therapeutics, Inc.

  公开号：US20190192691A1

  公开（公告）日：2019-06-27

  The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
• IDENTIFICATION AND TARGETED MODULATION OF GENE SIGNALING NETWORKS
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20210254056A1

  公开（公告）日：2021-08-19

  The present invention provides methods and compositions for the evaluation, alteration and/or optimization of gene signaling. Methods and systems are also provided which exploit the information generated in the identification of new targets and non-canonical signaling pathways.
• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSES PHARMACEUTIQUES
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2003087087A2

  公开（公告）日：2003-10-23

  The invention provides a compound for use in the prophylaxis or treatment of a disease state or condition mediated by a p38 MAP kinase such as rheumatoid arthritis and osteoarthritis; the compound being of the general formula (I): wherein U, T, V and W are each a nitrogen atom or a group CR4 provided that no more than three of U, T, V and W are nitrogen atoms; R0 is hydrogen, C1-4 hydrocarbyl, halogen or a group -A-R3; R1 is hydrogen, C1-4 hydrocarbyl or a group -A-R3; provided that only one of R0 and R1 is a group -A-R3; R2 is hydrogen, C1-4 hydrocarbyl or halogen; A is a carbon- or heteroatom-containing linker group having a linking chain length of one or two atoms; R3 is a monocyclic or bicyclic heteroaryl group containing from five to twelve ring members; each group R4 is independently selected from hydrogen, hydroxy, halogen, nitro, cyano, a monocyclic heterocyclic group having up to seven ring members, a group N(R5)2, a group C(O)N(R6)2, a group S02N(R6)2, a group Ra-Rb and a group Y; provided that no more than one group Y is present;